The Fuzzy Factor: Striving to Protect Patient Privacy in Big Data Sets

A major objective of former Vice President Joe Biden’s National Cancer Moonshot Initiative is breaking down silos and sharing cancer patients’ data across centers. This path is critical to bringing new dimensions to understanding the molecular biology of cancer, leading to the rapid identification of new therapeutic targets and accelerated development of molecularly informed cancer therapeutics.

Read More

Broadening Clinical Trial Participation

Patient enrollment in clinical trials has long been on the minds of oncologists and researchers. In 1990, fewer than 3 percent of patients were enrolled in clinical trials—which spurred then president-elect of the American Cancer Society, Walter Lawrence Jr., MD, to write an editorial calling for more concerted efforts. More than 25 years later, clinical trial participation hovers around 5 percent.

Read More

What Advances are Researchers Making in Treating Glioblastoma, McCain’s Cancer?

As we learned recently, Senator John McCain was diagnosed with glioblastoma multiforme, an aggressive form of central nervous system tumor that starts in the brain or spinal cord. It accounts for about 45 percent of all primary brain tumors, with about 11,000 diagnoses in men, women, and children each year.

Read More

FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More

A Targeted Therapy Next in Line for Biomarker-based Cancer Drug Approval?

recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib (LOXO-101), which showed promising results in adults and children with a variety of cancer types, all of which had one thing in common – fusions involving the gene TRK.

Read More

Catching Childhood Cancers Early: Insights Into the AACR Childhood Cancer Predisposition Workshop

There is perhaps nothing more painful for parents than receiving a cancer diagnosis for their child. Childhood cancers are generally rare, and in the United States, the death rates have …

Read More

Heading Into Summer, Please “Don’t Fry”

Today is National “Don’t Fry Day,” an initiative undertaken by the National Council on Skin Cancer Prevention to encourage sun safety awareness and to remind people to limit their exposure to ultraviolet (UV) radiation, which has been proven to cause skin cancer.

Read More

FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin

Tuesday marked a milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced its first approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers and not where in the body the tumor originated.

Read More

Scientist↔Survivor Program Participants Spend a Memorable Day on Capitol Hill

US Capitol Building

May is National Cancer Research Month, and for the past 10 years, leaders and members from the American Association for Cancer Research (AACR), the Association of American Cancer Institutes (AACI), and the American Society of Clinical Oncology (ASCO) have converged on Capitol Hill during May to share how cancer research is saving lives and transforming patient care.

Read More